• María

    Biography Winners Photo Gallery In Memorian . Biografía – María García Estrada   María was born on January 13th, 1981 in Santa Cruz de Tenerife. From an early age her life was linked to golf, sport in which she attained considerable success in the 1990s. She was particularly proud of attending the European Girls Team Continue Reading

    read more
  • Research

    The Maria Garcia-Estrada Foundation finances lines of research aimed at finding a cure for sarcoma, as well as research for finding effective treatments available to us today. The Maria Garcia-Estrada Foundation has funded since its inception in 2006, five research lines at the centers of cancer research at Duke University, North Carolina, USA, and Center Continue Reading

    read more
  • The Foundation

    Aims The main objective of the María García-Estrada Foundation, apart from rendering homage to her tireless spirit, is to provide answers to the two questions Maria asked herself during her tough days of battle against cancer, “What disease do I have? How can I get cured?” Up to this day, her two questions have no Continue Reading

    read more
  • Friends Club

    The Foundation, through donations, will be raising the funds necessary to cover the costs of the research For the Foundation to continue living we need to grow and ther´s no better way than having your support. Your ideas and your financial contribution is needed to combat this disease.. We want to pay tribute to Maria Continue Reading

    read more
  • Events

    Memorial Pro-Am Banesto Premium Tour – Latest Events              

    read more

5ft Investigation Line

The fifth line of investigation is being conducted because of the encouraging results of one of the drugs that the research team in the fourth line of research that the foundation has funded the Center for Cancer Research in Salamanca, led by researcher Dr. Henry of Álava.

Both Dr. de Alava and his research team have asked the Foundation to advance the fifth line of research, so that the Foundation has launched bureaucratic management to advance as soon as possible the next investigation.

The fifth line will begin in January 2012 with the hiring of a second investigator who will focus on drug research.

Studying the value of PARP1 as a therapeutic target in the SE.

PARP1 is overexpressed in more aggressive forms of Ewing sarcoma and maintains a role in the progression of tumor progression and resistance to conventional chemotherapeutic treatments against these tumors, making it a good therapeutic target in monotherapy and in combination with other drugs in the treatment of SE.

No hay comentarios aún.

Deja un comentario